Table SIII. Case-control studies with risk of bias

Study, year/ country	Patients	Intervention	Outcome	Adverse effects	Risk of bias
Chakkitta-kandiyil et al. (23), 2012/ Canada	*n* = 73 (M: 17/F: 56) (Type of IH Sup: 46, Mix: 14, Deep: 2) Sites Head and neck: 62 Trunk: 8 Extremities: 7	0.5% timolol GFS BD (62/73) 0.1% timolol GFS BD (11/73) Avg. at initiation: 4.27 months Avg duration of Tx: 3.4 months	Mean VAS in 0.5% timolol BD: (48±28) Mean VAS in 0.1% timolol BD: (24±29) 1 patient with mix IH had no response	1 patient had sleep disturbances, no rebound growth in 3–6 months of follow-up after discontinuation of treatment	1. Confounding: serious risk 2. Selection of participants: moderate risk 3. Measurement of intervention: low risk 4. Departure from intended intervention: moderate risk 5. Missing data: low risk 6. Measurement of outcome: moderate risk 7. Selection of reported result: low risk Overall bias: serious risk
Chambers et al. (24), 2012/ USA	*n* = 23 (Type of IH Sup: 5, Mix: 7, Deep: 1) Sites: 13 periocular	0.25% BD (13/23) Observation (10/23) Avg. at initiation: 4.8 months Avg duration of Tx: 2 months	Assessed by photography >50% decrease: (8/13) 0–50% decrease: (4/13) 1 grew in size	No side-effects, no rebound in 3–41 months of follow-up after discontinuation of treatment	1. Confounding: critical risk 2. Selection of participants: serious risk 3. Measurement of intervention: serious risk 4. Departure from intended intervention: serious risk 5. Missing data: low risk 6. Measurement of outcome: serious risk 7. Selection of reported result: low risk Overall bias: critical risk
Park et al. (35), 2014/ Korea	*n* = 102 (M: 23/F: 79) (Type of IH Sup: 102) Sites Head and neck: 47 Trunk: 26 Extremities: 32 Perineum: 6	0.5% timolol BD (61/102) PDL + 0.5% timolol (41/102) Avg duration of Tx: 12 months	Assessed by photography >75–100% decrease: (14/61) 50–74% decrease: (14/61) 25–49% decrease: (11/61) 0–24% decrease: (19/61) No improvement: (3/61)	No side-effects, no rebound (follow-up period not clearly defined)	1. Confounding: serious risk 2. Selection of participants: serious risk 3. Measurement of intervention: moderate risk 4. Departure from intended intervention: low risk 5. Missing data: serious risk 6. Measurement of outcome: low risk 7. Selection of reported result: moderate risk Overall bias: serious risk
Qiu et al. (37), 2013/USA	*n* = 145 (M: 24/F: 27) (Type of IH Sup: 51) Sites Head and neck: 12 Trunk: 4 Extremities: 4	0.5% timolol TDS (51/145) Imiquimod (94/145) Avg. at initiation: 3.07 months Avg duration of Tx: 4.43 months	Mean VAS in 0.5% timolol TDS: (78.5±20.43) Mean VAS in Imiquimod: (67.38±26.01)	No side-effects with timolol, Crusting in imiquimod during treatment, no rebound growth documented	1. Confounding: serious risk 2. Selection of participants: moderate risk 3. Measurement of intervention: low risk 4. Departure from intended intervention: serious risk 5. Missing data: low risk 6. Measurement of outcome: low risk 7. Selection of reported result: low risk Overall bias: moderate risk
Tawfik et al. (42), 2015/ Egypt	*n* = 60 (M: 7/F: 23) (Type of IH Sup: 24, Mix: 6) Sites Head and neck: 19 Trunk: 4 Extremities: 7	0.5% timolol BD (30/60) PDL Nd: Yag (30/60) Avg. at initiation: 6 months Avg duration of Tx: 4 months	Assessed by photography >76–100% decrease: (9/30) 51–75% decrease: (9/30) 26–50% decrease: (4/30) <25% decrease: (4/30) No improvement (4/30)	1 patient had sleep disturbances, no rebound growth in 3 months of follow-up after discontinuation of treatment	1. Confounding: low risk 2. Selection of participants: low risk 3. Measurement of intervention: moderate risk 4. Departure from intended intervention: low risk 5. Missing data: low risk 6. Measurement of outcome: low risk 7. Selection of reported result: low risk Overall bias: moderate risk
Yu et al. (48), 2013/China	*n* = 123 (M: 47/F: 77) (Type of IH Sup: 101) Sites Head and neck: 65 Trunk: 27 Extremities: 32	0.5% timolol TDS (101/123) Observation (23/123) Avg. at initiation: 6 months Avg duration of Tx: 4 months	Assessed by photography Promoted regression: (57/101) Controlled growth: (36/101) Ineffective: (8/101)	No side-effects reported during 4 months of treatment, no rebound growth documented	1. Confounding: serious risk 2. Selection of participants: moderate risk 3. Measurement of intervention: serious risk 4. Departure from intended intervention: serious risk 5. Missing data: low risk 6. Measurement of outcome: moderate risk 7. Selection of reported result: low risk Overall bias: serious risk

IH: infantile hemangioma; Sup: superficial hemangioma; Avg: average; Tx: treatment; months: months; VAS: visual analogue scale; BD: twice daily. GFS: Gel forming solution; TDS: thrice daily.